Tumor microenvironment: Bone marrow-mesenchymal stem cells as key players

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1836, Issue 2, 2013, Pages 321-335

  Barcellos de Souza, Pedro ^a,b   Gori, Valentina ^c   Bambi, Franco ^c   Chiarugi, Paola ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b MINISTRY OF EDUCATION OF BRAZIL   (Brazil)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Bone marrow derived mesenchymal stem cells; Cancer associated fibroblasts; Evasion from tumor site; Metastatic niche; Tumor progression; Tumor tropism

Indexed keywords

ADAPTIVE IMMUNITY; CANCER GROWTH; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL TRANSDIFFERENTIATION; CELLULAR DISTRIBUTION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; MESENCHYMAL STEM CELL; METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STEM CELL NICHE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; TUMOR VASCULARIZATION;

BONE MARROW-DERIVED MESENCHYMAL STEM CELLS; CANCER-ASSOCIATED FIBROBLASTS; EVASION FROM TUMOR SITE; METASTATIC NICHE; TUMOR PROGRESSION; TUMOR TROPISM;

ANIMALS; BONE MARROW; CELL DIFFERENTIATION; HUMANS; MESENCHYMAL STROMAL CELLS; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84887522014     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2013.10.004     Document Type: Review

References (160)

1. Fukuchi Y., Nakajima H., Sugiyama D., Hirose I., Kitamura T., Tsuji K. Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Stem Cells 2004, 22:649-658.
2. Ilancheran S., Moodley Y., Manuelpillai U. Human fetal membranes: a source of stem cells for tissue regeneration and repair?. Placenta 2009, 30:2-10.
3. Mosna F., Sensebe L., Krampera M. Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide. Stem Cells Dev. 2010, 19:1449-1470.
4. Vellasamy S., Sandrasaigaran P., Vidyadaran S., George E., Ramasamy R. Isolation and characterisation of mesenchymal stem cells derived from human placenta tissue. World J. Stem Cells 2012, 4:53-61.
5. Batsali A.K., Kastrinaki M.C., Papadaki H.A., Pontikoglou C. Mesenchymal stem cells derived from Wharton's Jelly of the umbilical cord: biological properties and emerging clinical applications. Curr. Stem Cell Res. Ther. 2013, 8:144-155.
6. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop D., Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
7. Miao Z., Jin J., Chen L., Zhu J., Huang W., Zhao J., Qian H., Zhang X. Isolation of mesenchymal stem cells from human placenta: comparison with human bone marrow mesenchymal stem cells. Cell Biol. Int. 2006, 30:681-687.
8. Li M., Ikehara S. Bone-marrow-derived mesenchymal stem cells for organ repair. Stem Cells Int. 2013, 2013:132642.
9. Direkze N.C., Forbes S.J., Brittan M., Hunt T., Jeffery R., Preston S.L., Poulsom R., Hodivala-Dilke K., Alison M.R., Wright N.A. Multiple organ engraftment by bone-marrow-derived myofibroblasts and fibroblasts in bone-marrow-transplanted mice. Stem Cells 2003, 21:514-520.
10. Wang C.H., Cherng W.J., Yang N.I., Kuo L.T., Hsu C.M., Yeh H.I., Lan Y.J., Yeh C.H., Stanford W.L. Late-outgrowth endothelial cells attenuate intimal hyperplasia contributed by mesenchymal stem cells after vascular injury. Arterioscler. Thromb. Vasc. Biol. 2008, 28:54-60.
11. Schafer M., Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat. Rev. Mol. Cell Biol. 2008, 9:628-638.
12. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., Richardson A.L., Polyak K., Tubo R., Weinberg R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
13. Dwyer R.M., Potter-Beirne S.M., Harrington K.A., Lowery A.J., Hennessy E., Murphy J.M., Barry F.P., O'Brien T., Kerin M.J. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin. Cancer Res. 2007, 13:5020-5027.
14. Rattigan Y., Hsu J.M., Mishra P.J., Glod J., Banerjee D. Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu. Exp. Cell Res. 2010, 316:3417-3424.
15. Zhang Y., Yang P., Sun T., Li D., Xu X., Rui Y., Li C., Chong M., Ibrahim T., Mercatali L., Amadori D., Lu X., Xie D., Li Q.J., Wang X.F. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat. Cell Biol. 2013, 15:284-294.
16. Gutova M., Najbauer J., Frank R.T., Kendall S.E., Gevorgyan A., Metz M.Z., Guevorkian M., Edmiston M., Zhao D., Glackin C.A., Kim S.U., Aboody K.S. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells 2008, 26:1406-1413.
17. Suzuki K., Sun R., Origuchi M., Kanehira M., Takahata T., Itoh J., Umezawa A., Kijima H., Fukuda S., Saijo Y. Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol. Med. 2011, 17:579-587.
18. Beckermann B.M., Kallifatidis G., Groth A., Frommhold D., Apel A., Mattern J., Salnikov A.V., Moldenhauer G., Wagner W., Diehlmann A., Saffrich R., Schubert M., Ho A.D., Giese N., Buchler M.W., Friess H., Buchler P., Herr I. VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br. J. Cancer 2008, 99:622-631.
19. Hung S.C., Deng W.P., Yang W.K., Liu R.S., Lee C.C., Su T.C., Lin R.J., Yang D.M., Chang C.W., Chen W.H., Wei H.J., Gelovani J.G. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin. Cancer Res. 2005, 11:7749-7756.
20. Shinagawa K., Kitadai Y., Tanaka M., Sumida T., Kodama M., Higashi Y., Tanaka S., Yasui W., Chayama K. Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int. J. Cancer 2010, 127:2323-2333.
21. Spaeth E.L., Dembinski J.L., Sasser A.K., Watson K., Klopp A., Hall B., Andreeff M., Marini F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PloS one 2009, 4:e4992.
22. Komarova S., Roth J., Alvarez R., Curiel D.T., Pereboeva L. Targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor. J. Ovarian Res. 2010, 3:12.
23. Coffelt S.B., Marini F.C., Watson K., Zwezdaryk K.J., Dembinski J.L., LaMarca H.L., Tomchuck S.L., Honer zu Bentrup K., Danka E.S., Henkle S.L., Scandurro A.B. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3806-3811.
24. Ye H., Cheng J., Tang Y., Liu Z., Xu C., Liu Y., Sun Y. Human bone marrow-derived mesenchymal stem cells produced TGFbeta contributes to progression and metastasis of prostate cancer. Cancer Invest. 2012, 30:513-518.
25. Jung Y., Kim J.K., Shiozawa Y., Wang J., Mishra A., Joseph J., Berry J.E., McGee S., Lee E., Sun H., Wang J., Jin T., Zhang H., Dai J., Krebsbach P.H., Keller E.T., Pienta K.J., Taichman R.S. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat. Commun. 2013, 4:1795.
26. Studeny M., Marini F.C., Champlin R.E., Zompetta C., Fidler I.J., Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002, 62:3603-3608.
27. Nakamizo A., Marini F., Amano T., Khan A., Studeny M., Gumin J., Chen J., Hentschel S., Vecil G., Dembinski J., Andreeff M., Lang F.F. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 2005, 65:3307-3318.
28. Schichor C., Birnbaum T., Etminan N., Schnell O., Grau S., Miebach S., Aboody K., Padovan C., Straube A., Tonn J.C., Goldbrunner R. Vascular endothelial growth factor A contributes to glioma-induced migration of human marrow stromal cells (hMSC). Exp. Neurol. 2006, 199:301-310.
29. Khakoo A.Y., Pati S., Anderson S.A., Reid W., Elshal M.F., Rovira I.I., Nguyen A.T., Malide D., Combs C.A., Hall G., Zhang J., Raffeld M., Rogers T.B., Stetler-Stevenson W., Frank J.A., Reitz M., Finkel T. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J. Exp. Med. 2006, 203:1235-1247.
30. Xu W.T., Bian Z.Y., Fan Q.M., Li G., Tang T.T. Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. Cancer Lett. 2009, 281:32-41.
31. Bergfeld S.A., DeClerck Y.A. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev. 2010, 29:249-261.
32. Ishii G., Sangai T., Oda T., Aoyagi Y., Hasebe T., Kanomata N., Endoh Y., Okumura C., Okuhara Y., Magae J., Emura M., Ochiya T., Ochiai A. Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. Biochem. Biophys. Res. Commun. 2003, 309:232-240.
33. Direkze N.C., Hodivala-Dilke K., Jeffery R., Hunt T., Poulsom R., Oukrif D., Alison M.R., Wright N.A. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res. 2004, 64:8492-8495.
34. Quante M., Tu S.P., Tomita H., Gonda T., Wang S.S., Takashi S., Baik G.H., Shibata W., Diprete B., Betz K.S., Friedman R., Varro A., Tycko B., Wang T.C. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011, 19:257-272.
35. Mishra P.J., Mishra P.J., Humeniuk R., Medina D.J., Alexe G., Mesirov J.P., Ganesan S., Glod J.W., Banerjee D. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 2008, 68:4331-4339.
36. Kidd S., Spaeth E., Watson K., Burks J., Lu H., Klopp A., Andreeff M., Marini F.C. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PloS one 2012, 7:e30563.
37. Sordi V., Malosio M.L., Marchesi F., Mercalli A., Melzi R., Giordano T., Belmonte N., Ferrari G., Leone B.E., Bertuzzi F., Zerbini G., Allavena P., Bonifacio E., Piemonti L. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005, 106:419-427.
38. Von Luttichau I., Notohamiprodjo M., Wechselberger A., Peters C., Henger A., Seliger C., Djafarzadeh R., Huss R., Nelson P.J. Human adult CD34-progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Stem Cells Dev. 2005, 14:329-336.
39. Honczarenko M., Le Y., Swierkowski M., Ghiran I., Glodek A.M., Silberstein L.E. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006, 24:1030-1041.
40. Ringe J., Strassburg S., Neumann K., Endres M., Notter M., Burmester G.R., Kaps C., Sittinger M. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J. Cell. Biochem. 2007, 101:135-146.
41. Spaeth E., Klopp A., Dembinski J., Andreeff M., Marini F. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 2008, 15:730-738.
42. Ruster B., Gottig S., Ludwig R.J., Bistrian R., Muller S., Seifried E., Gille J., Henschler R. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006, 108:3938-3944.
43. Ries C., Egea V., Karow M., Kolb H., Jochum M., Neth P. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood 2007, 109:4055-4063.
44. Ho I.A., Chan K.Y., Ng W.H., Guo C.M., Hui K.M., Cheang P., Lam P.Y. Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma. Stem Cells 2009, 27:1366-1375.
45. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
46. Annabi B., Lee Y.T., Turcotte S., Naud E., Desrosiers R.R., Champagne M., Eliopoulos N., Galipeau J., Beliveau R. Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation. Stem Cells 2003, 21:337-347.
47. Proulx-Bonneau S., Guezguez A., Annabi B. A concerted HIF-1alpha/MT1-MMP signalling axis regulates the expression of the 3BP2 adaptor protein in hypoxic mesenchymal stromal cells. PloS one 2011, 6:e21511.
48. Rosova I., Dao M., Capoccia B., Link D., Nolta J.A. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 2008, 26:2173-2182.
49. Eltzschig H.K., Carmeliet P. Hypoxia and inflammation. N. Engl. J. Med. 2011, 364:656-665.
50. Meng E., Guo Z., Wang H., Jin J., Wang J., Wang H., Wu C., Wang L. High mobility group box 1 protein inhibits the proliferation of human mesenchymal stem cells and promotes their migration and differentiation along osteoblastic pathway. Stem Cells Dev. 2008, 17:805-813.
51. Lotfi R., Eisenbacher J., Solgi G., Fuchs K., Yildiz T., Nienhaus C., Rojewski M.T., Schrezenmeier H. Human mesenchymal stem cells respond to native but not oxidized damage associated molecular pattern molecules from necrotic (tumor) material. Eur. J. Immunol. 2011, 41:2021-2028.
52. Pistoia V., Raffaghello L. Damage-associated molecular patterns (DAMPs) and mesenchymal stem cells: a matter of attraction and excitement. Eur. J. Immunol. 2011, 41:1828-1831.
53. Micallef L., Vedrenne N., Billet F., Coulomb B., Darby I.A., Desmouliere A. The myofibroblast, multiple origins for major roles in normal and pathological tissue repair. Fibrogenesis Tissue Repair 2012, 5(Suppl. 1):S5.
54. 2+. Stem Cells Dev. 2012, 21:1418-1428.
55. Cao Y., Meng Y., Sun Z., Liao L.M., Han Q., Li J., Liu Y.N., Zhao C.H. [Potential of human adipose tissue derived adult stem cells differentiate into endothelial cells], Zhongguo yi xue ke xue yuan xue bao. Acta Acad. Med. Sin. 2005, 27:678-682.
56. Fischer L.J., McIlhenny S., Tulenko T., Golesorkhi N., Zhang P., Larson R., Lombardi J., Shapiro I., DiMuzio P.J. Endothelial differentiation of adipose-derived stem cells: effects of endothelial cell growth supplement and shear force. J. Surg. Res. 2009, 152:157-166.
57. Oswald J., Boxberger S., Jorgensen B., Feldmann S., Ehninger G., Bornhauser M., Werner C. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004, 22:377-384.
58. Janeczek Portalska K., Leferink A., Groen N., Fernandes H., Moroni L., van Blitterswijk C., de Boer J. Endothelial differentiation of mesenchymal stromal cells. PloS one 2012, 7:e46842.
59. Au P., Tam J., Fukumura D., Jain R.K. Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood 2008, 111:4551-4558.
60. Bexell D., Gunnarsson S., Tormin A., Darabi A., Gisselsson D., Roybon L., Scheding S., Bengzon J. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol. Ther. 2009, 17:183-190.
61. Birnbaum T., Hildebrandt J., Nuebling G., Sostak P., Straube A. Glioblastoma-dependent differentiation and angiogenic potential of human mesenchymal stem cells in vitro. J. Neuro-Oncol. 2011, 105:57-65.
62. Dore-Duffy P. Pericytes: pluripotent cells of the blood brain barrier. Curr. Pharm. Des. 2008, 14:1581-1593.
63. Freisinger E., Cramer C., Xia X., Murthy S.N., Slakey D.P., Chiu E., Newsome E.R., Alt E.U., Izadpanah R. Characterization of hematopoietic potential of mesenchymal stem cells. J. Cell. Physiol. 2010, 225:888-897.
64. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
65. Djouad F., Plence P., Bony C., Tropel P., Apparailly F., Sany J., Noel D., Jorgensen C. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003, 102:3837-3844.
66. Zhu W., Xu W., Jiang R., Qian H., Chen M., Hu J., Cao W., Han C., Chen Y. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp. Mol. Pathol. 2006, 80:267-274.
67. Liu S., Ginestier C., Ou S.J., Clouthier S.G., Patel S.H., Monville F., Korkaya H., Heath A., Dutcher J., Kleer C.G., Jung Y., Dontu G., Taichman R., Wicha M.S. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 2011, 71:614-624.
68. Bian Z.Y., Fan Q.M., Li G., Xu W.T., Tang T.T. Human mesenchymal stem cells promote growth of osteosarcoma: involvement of interleukin-6 in the interaction between human mesenchymal stem cells and Saos-2. Cancer Sci. 2010, 101:2554-2560.
69. Tsai K.S., Yang S.H., Lei Y.P., Tsai C.C., Chen H.W., Hsu C.Y., Chen L.L., Wang H.W., Miller S.A., Chiou S.H., Hung M.C., Hung S.C. Mesenchymal stem cells promote formation of colorectal tumors in mice. Gastroenterology 2011, 141:1046-1056.
70. De Boeck A., Pauwels P., Hensen K., Rummens J.L., Westbroek W., Hendrix A., Maynard D., Denys H., Lambein K., Braems G., Gespach C., Bracke M., De Wever O. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. Gut 2013, 62:550-560.
71. Tu B., Du L., Fan Q.M., Tang Z., Tang T.T. STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. Cancer Lett. 2012, 325:80-88.
72. Heilborn J.D., Nilsson M.F., Jimenez C.I., Sandstedt B., Borregaard N., Tham E., Sorensen O.E., Weber G., Stahle M. Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells. Int. J. Cancer 2005, 114:713-719.
73. Coffelt S.B., Waterman R.S., Florez L., Honer zu Bentrup K., Zwezdaryk K.J., Tomchuck S.L., LaMarca H.L., Danka E.S., Morris C.A., Scandurro A.B. Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. Int. J. Cancer 2008, 122:1030-1039.
74. von Haussen J., Koczulla R., Shaykhiev R., Herr C., Pinkenburg O., Reimer D., Wiewrodt R., Biesterfeld S., Aigner A., Czubayko F., Bals R. The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer 2008, 59:12-23.
75. Anton K., Banerjee D., Glod J. Macrophage-associated mesenchymal stem cells assume an activated, migratory, pro-inflammatory phenotype with increased IL-6 and CXCL10 secretion. PloS one 2012, 7:e35036.
76. Onder T.T., Gupta P.B., Mani S.A., Yang J., Lander E.S., Weinberg R.A. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008, 68:3645-3654.
77. Giannoni E., Parri M., Chiarugi P. EMT and oxidative stress: a bidirectional interplay affecting tumor malignancy. Antioxid. Redox Signal. 2012, 16:1248-1263.
78. Wang M.L., Pan C.M., Chiou S.H., Chen W.H., Chang H.Y., Lee O.K., Hsu H.S., Wu C.W. Oncostatin m modulates the mesenchymal-epithelial transition of lung adenocarcinoma cells by a mesenchymal stem cell-mediated paracrine effect. Cancer Res. 2012, 72:6051-6064.
79. Martin F.T., Dwyer R.M., Kelly J., Khan S., Murphy J.M., Curran C., Miller N., Hennessy E., Dockery P., Barry F.P., O'Brien T., Kerin M.J. Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res. Treat. 2010, 124:317-326.
80. Xu Q., Wang L., Li H., Han Q., Li J., Qu X., Huang S., Zhao R.C. Mesenchymal stem cells play a potential role in regulating the establishment and maintenance of epithelial-mesenchymal transition in MCF7 human breast cancer cells by paracrine and induced autocrine TGF-beta. Int. J. Oncol. 2012, 41:959-968.
81. El-Haibi C.P., Bell G.W., Zhang J., Collmann A.Y., Wood D., Scherber C.M., Csizmadia E., Mariani O., Zhu C., Campagne A., Toner M., Bhatia S.N., Irimia D., Vincent-Salomon A., Karnoub A.E. Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:17460-17465.
82. Jing Y., Han Z., Liu Y., Sun K., Zhang S., Jiang G., Li R., Gao L., Zhao X., Wu D., Cai X., Wu M., Wei L. Mesenchymal stem cells in inflammation microenvironment accelerates hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition. PloS one 2012, 7:e43272.
83. Lis R., Touboul C., Raynaud C.M., Malek J.A., Suhre K., Mirshahi M., Rafii A. Mesenchymal cell interaction with ovarian cancer cells triggers pro-metastatic properties. PloS one 2012, 7:e38340.
84. Shinagawa K., Kitadai Y., Tanaka M., Sumida T., Onoyama M., Ohnishi M., Ohara E., Higashi Y., Tanaka S., Yasui W., Chayama K. Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer. Int. J. Cancer 2013, 132:813-823.
85. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., Carey V.J., Richardson A.L., Weinberg R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
86. Cirri P., Chiarugi P. Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev. 2012, 31:195-208.
87. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J. Clin. Invest. 2009, 119:1417-1419.
88. Giannoni E., Bianchini F., Masieri L., Serni S., Torre E., Calorini L., Chiarugi P. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010, 70:6945-6956.
89. Giannoni E., Bianchini F., Calorini L., Chiarugi P. Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. Antioxid. Redox Signal. 2011, 14:2361-2371.
90. Orimo A., Weinberg R.A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006, 5:1597-1601.
91. Giannoni E., Taddei M.L., Parri M., Bianchini F., Santosuosso M., Grifantini R., Fibbi G., Mazzanti B., Calorini L., Chiarugi P. EphA2-mediated mesenchymal-amoeboid transition induced by endothelial progenitor cells enhances metastatic spread due to cancer-associated fibroblasts. J. Mol. Med. 2013, 91:103-115.
92. Comito G., Giannoni E., Segura C.P., Barcellos-de-Souza P., Raspollini M.R., Baroni G., Lanciotti M., Serni S., Chiarugi P. Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. Oncogene 2013.
93. Fiaschi T., Giannoni E., Taddei M.L., Cirri P., Marini A., Pintus G., Nativi C., Richichi B., Scozzafava A., Carta F., Torre E., Supuran C.T., Chiarugi P. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle 2013, 12:1791-1801.
94. Fiaschi T., Marini A., Giannoni E., Taddei M.L., Gandellini P., De Donatis A., Lanciotti M., Serni S., Cirri P., Chiarugi P. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res. 2012, 72:5130-5140.
95. Pavlides S., Whitaker-Menezes D., Castello-Cros R., Flomenberg N., Witkiewicz A.K., Frank P.G., Casimiro M.C., Wang C., Fortina P., Addya S., Pestell R.G., Martinez-Outschoorn U.E., Sotgia F., Lisanti M.P. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009, 8:3984-4001.
96. Bonuccelli G., Tsirigos A., Whitaker-Menezes D., Pavlides S., Pestell R.G., Chiavarina B., Frank P.G., Flomenberg N., Howell A., Martinez-Outschoorn U.E., Sotgia F., Lisanti M.P. Ketones and lactate "fuel" tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 2010, 9:3506-3514.
97. Martinez-Outschoorn U.E., Pavlides S., Howell A., Pestell R.G., Tanowitz H.B., Sotgia F., Lisanti M.P. Stromal-epithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvironment. Int. J. Biochem. Cell Biol. 2011, 43:1045-1051.
98. Giatromanolaki A., Koukourakis M.I., Koutsopoulos A., Mendrinos S., Sivridis E. The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer. Cancer Biol. Ther. 2012, 13:1284-1289.
99. Koukourakis M.I., Giatromanolaki A., Harris A.L., Sivridis E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 2006, 66:632-637.
100. Rattigan Y.I., Patel B.B., Ackerstaff E., Sukenick G., Koutcher J.A., Glod J.W., Banerjee D. Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment. Exp. Cell Res. 2012, 318:326-335.
101. Yan X.L., Jia Y.L., Chen L., Zeng Q., Zhou J.N., Fu C.J., Chen H.X., Yuan H.F., Li Z.W., Shi L., Xu Y.C., Wang J.X., Zhang X.M., He L.J., Zhai C., Yue W., Pei X.T. Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinoma progression: role of the S100A4-miR155-SOCS1-MMP9 axis. Hepatology 2013, 57:2274-2286.
102. Sergina N.V., Moasser M.M. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol. Med. 2007, 13:527-534.
103. Lecomte J., Masset A., Blacher S., Maertens L., Gothot A., Delgaudine M., Bruyere F., Carnet O., Paupert J., Illemann M., Foidart J.M., Lund I.K., Hoyer-Hansen G., Noel A. Bone marrow-derived myofibroblasts are the providers of pro-invasive matrix metalloproteinase 13 in primary tumor. Neoplasia 2012, 14:943-951.
104. Shangguan L., Ti X., Krause U., Hai B., Zhao Y., Yang Z., Liu F. Inhibition of TGF-beta/Smad signaling by BAMBI blocks differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and abolishes their protumor effects. Stem Cells 2012, 30:2810-2819.
105. Marjon P.L., Bobrovnikova-Marjon E.V., Abcouwer S.F. Expression of the pro-angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 by human breast carcinomas is responsive to nutrient deprivation and endoplasmic reticulum stress. Mol. Cancer 2004, 3:4.
106. Fukumura D., Jain R.K. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc. Res. 2007, 74:72-84.
107. Potier E., Ferreira E., Andriamanalijaona R., Pujol J.P., Oudina K., Logeart-Avramoglou D., Petite H. Hypoxia affects mesenchymal stromal cell osteogenic differentiation and angiogenic factor expression. Bone 2007, 40:1078-1087.
108. Liu Y., Han Z.P., Zhang S.S., Jing Y.Y., Bu X.X., Wang C.Y., Sun K., Jiang G.C., Zhao X., Li R., Gao L., Zhao Q.D., Wu M.C., Wei L.X. Effects of inflammatory factors on mesenchymal stem cells and their role in the promotion of tumor angiogenesis in colon cancer. J. Biol. Chem. 2011, 286:25007-25015.
109. Secchiero P., Zorzet S., Tripodo C., Corallini F., Melloni E., Caruso L., Bosco R., Ingrao S., Zavan B., Zauli G. Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. PloS one 2010, 5:e11140.
110. Otsu K., Das S., Houser S.D., Quadri S.K., Bhattacharya S., Bhattacharya J. Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood 2009, 113:4197-4205.
111. Ho I.A., Toh H.C., Ng W.H., Teo Y.L., Guo C.M., Hui K.M., Lam P.Y. Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Stem Cells 2013, 31:146-155.
112. Le Blanc K., Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system, Nature reviews. Immunology 2012, 12:383-396.
113. Sica A., Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 2012, 122:787-795.
114. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
115. Chen L., Tredget E.E., Wu P.Y., Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PloS one 2008, 3:e1886.
116. Kim J., Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp. Hematol. 2009, 37:1445-1453.
117. Maggini J., Mirkin G., Bognanni I., Holmberg J., Piazzon I.M., Nepomnaschy I., Costa H., Canones C., Raiden S., Vermeulen M., Geffner J.R. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PloS one 2010, 5:e9252.
118. Francois M., Romieu-Mourez R., Li M., Galipeau J. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol. Ther. 2012, 20:187-195.
119. Croitoru-Lamoury J., Lamoury F.M., Caristo M., Suzuki K., Walker D., Takikawa O., Taylor R., Brew B.J. Interferon-gamma regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO). PloS one 2011, 6:e14698.
120. Mougiakakos D., Jitschin R., Johansson C.C., Okita R., Kiessling R., Le Blanc K. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 2011, 117:4826-4835.
121. Romieu-Mourez R., Francois M., Boivin M.N., Bouchentouf M., Spaner D.E., Galipeau J. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J. Immunol. 2009, 182:7963-7973.
122. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., Grisanti S., Gianni A.M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
123. Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., Giunti D., Ceravolo A., Cazzanti F., Frassoni F., Mancardi G., Uccelli A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106:1755-1761.
124. Najar M., Raicevic G., Boufker H.I., Fayyad Kazan H., De Bruyn C., Meuleman N., Bron D., Toungouz M., Lagneaux L. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell. Immunol. 2010, 264:171-179.
125. Plumas J., Chaperot L., Richard M.J., Molens J.P., Bensa J.C., Favrot M.C. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 2005, 19:1597-1604.
126. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., Dazzi F. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101:3722-3729.
127. Prigione I., Benvenuto F., Bocca P., Battistini L., Uccelli A., Pistoia V. Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells 2009, 27:693-702.
128. Bouffi C., Bony C., Courties G., Jorgensen C., Noel D. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PloS one 2010, 5:e14247.
129. Nemeth K., Keane-Myers A., Brown J.M., Metcalfe D.D., Gorham J.D., Bundoc V.G., Hodges M.G., Jelinek I., Madala S., Karpati S., Mezey E. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:5652-5657.
130. Groh M.E., Maitra B., Szekely E., Koc O.N. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp. Hematol. 2005, 33:928-934.
131. Ghannam S., Pene J., Torcy-Moquet G., Jorgensen C., Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J. Immunol. 2010, 185:302-312.
132. English K., Barry F.P., Mahon B.P. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol. Lett. 2008, 115:50-58.
133. De Miguel M.P., Fuentes-Julian S., Blazquez-Martinez A., Pascual C.Y., Aller M.A., Arias J., Arnalich-Montiel F. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr. Mol. Med. 2012, 12:574-591.
134. Waterman R.S., Tomchuck S.L., Henkle S.L., Betancourt A.M. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PloS one 2010, 5:e10088.
135. Waterman R.S., Henkle S.L., Betancourt A.M. Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis. PloS one 2012, 7:e45590.
136. English K. Mechanisms of mesenchymal stromal cell immunomodulation. Immunol. Cell Biol. 2013, 91:19-26.
137. Han Z., Tian Z., Lv G., Zhang L., Jiang G., Sun K., Wang C., Bu X., Li R., Shi Y., Wu M., Wei L. Immunosuppressive effect of bone marrow-derived mesenchymal stem cells in inflammatory microenvironment favours the growth of B16 melanoma cells. J. Cell Mol. Med. 2011, 15:2343-2352.
138. Talmadge J.E., Fidler I.J. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010, 70:5649-5669.
139. van de Stolpe A. On the origin and destination of cancer stem cells: a conceptual evaluation. Am. J. Cancer Res. 2013, 3:107-116.
140. Hurst D.R., Welch D.R. A MSC-ing link in metastasis?. Nat. Med. 2007, 13:1289-1291.
141. Munoz P., Iliou M.S., Esteller M. Epigenetic alterations involved in cancer stem cell reprogramming. Mol. Oncol. 2012, 6:620-636.
142. Yu Z., Pestell T.G., Lisanti M.P., Pestell R.G. Cancer stem cells. Int. J. Biochem. Cell Biol. 2012, 44:2144-2151.
143. Li H.J., Reinhardt F., Herschman H.R., Weinberg R.A. Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov. 2012, 2:840-855.
144. Fierro F.A., Sierralta W.D., Epunan M.J., Minguell J.J. Marrow-derived mesenchymal stem cells: role in epithelial tumor cell determination. Clin. Exp. Metastasis 2004, 21:313-319.
145. Corcoran K.E., Trzaska K.A., Fernandes H., Bryan M., Taborga M., Srinivas V., Packman K., Patel P.S., Rameshwar P. Mesenchymal stem cells in early entry of breast cancer into bone marrow. PloS one 2008, 3:e2563.
146. Duda D.G., Duyverman A.M., Kohno M., Snuderl M., Steller E.J., Fukumura D., Jain R.K. Malignant cells facilitate lung metastasis by bringing their own soil. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21677-21682.
147. Rappa G., Mercapide J., Lorico A. Spontaneous formation of tumorigenic hybrids between breast cancer and multipotent stromal cells is a source of tumor heterogeneity. Am. J. Pathol. 2012, 180:2504-2515.
148. Chang J.W., Tsai H.L., Chen C.W., Yang H.W., Yang A.H., Yang L.Y., Wang P.S., Ng Y.Y., Lin T.L., Lee O.K. Conditioned mesenchymal stem cells attenuate progression of chronic kidney disease through inhibition of epithelial-to-mesenchymal transition and immune modulation. J. Cell Mol. Med. 2012, 16:2935-2949.
149. Grisendi G., Bussolari R., Veronesi E., Piccinno S., Burns J.S., De Santis G., Loschi P., Pignatti M., Di Benedetto F., Ballarin R., Di Gregorio C., Guarneri V., Piccinini L., Horwitz E.M., Paolucci P., Conte P., Dominici M. Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers. Am. J. Cancer Res. 2011, 1:787-805.
150. Adesida A.B., Mulet-Sierra A., Jomha N.M. Hypoxia mediated isolation and expansion enhances the chondrogenic capacity of bone marrow mesenchymal stromal cells. Stem Cell Res. Ther. 2012, 3:9.
151. Malgieri A., Kantzari E., Patrizi M.P., Gambardella S. Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. Int. J. Clin. Exp. Med. 2010, 3:248-269.
152. O'Cearbhaill E.D., Murphy M., Barry F., McHugh P.E., Barron V. Behavior of human mesenchymal stem cells in fibrin-based vascular tissue engineering constructs. Ann. Biomed. Eng. 2010, 38:649-657.
153. Tocci A., Forte L. Mesenchymal stem cell: use and perspectives. Hematol. J. 2003, 4:92-96.
154. Abdi R., Fiorina P., Adra C.N., Atkinson M., Sayegh M.H. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 2008, 57:1759-1767.
155. Vogel W., Grunebach F., Messam C.A., Kanz L., Brugger W., Buhring H.J. Heterogeneity among human bone marrow-derived mesenchymal stem cells and neural progenitor cells. Haematologica 2003, 88:126-133.
156. Rasini V., Dominici M., Kluba T., Siegel G., Lusenti G., Northoff H., Horwitz E.M., Schafer R. Mesenchymal stromal/stem cells markers in the human bone marrow. Cytotherapy 2013, 15:292-306.
157. Al-Nbaheen M., Vishnubalaji R., Ali D., Bouslimi A., Al-Jassir F., Megges M., Prigione A., Adjaye J., Kassem M., Aldahmash A. Human stromal (mesenchymal) stem cells from bone marrow, adipose tissue and skin exhibit differences in molecular phenotype and differentiation potential. Stem Cell Rev. 2013, 9:32-43.
158. Song L., Webb N.E., Song Y., Tuan R.S. Identification and functional analysis of candidate genes regulating mesenchymal stem cell self-renewal and multipotency. Stem Cells 2006, 24:1707-1718.
159. Watson J.T., Foo T., Wu J., Moed B.R., Thorpe M., Schon L., Zhang Z. CD271 as a marker for mesenchymal stem cells in bone marrow versus umbilical cord blood. Cells Tissues Organs 2013, 197(6):496-504.
160. Nasef A., Zhang Y.Z., Mazurier C., Bouchet S., Bensidhoum M., Francois S., Gorin N.C., Lopez M., Thierry D., Fouillard L., Chapel A. Selected Stro-1-enriched bone marrow stromal cells display a major suppressive effect on lymphocyte proliferation. Int. J. Lab. Hematol. 2009, 31:9-19.